Clinical Program BL8040

Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions, hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA) with BL8040

“BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions

Efficacy and safety study, in collaboration with MD Anderson Cancer Center,

will assess BL-8040 as combination treatment with immunosuppressants

Interim results of study, in patients with hypoplastic myelodysplastic

syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016″

November 23rd, 2015|Clinical Program BL8040, Recent News|

Positive Clinical Results from First Part of Phase 2 Trial in r/r AML with BL8040

“BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AML

 

– Data strongly suggest BL-8040 has potent anti-leukemic activity

in combination with Ara-C in AML “-

November 5th, 2015|Clinical Program BL8040, Recent News|

Initiation of Phase 2b Trial for Novel AML Consolidation Treatment with BL8040

BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment

 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, will enroll up to 194 patients, randomized

in 1:1 ratio, at up to 25 sites in Germany 

August 17th, 2015|Clinical Program BL8040, Recent News|

Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment with BL8040

BioLineRx Presented Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment with BL8040 at European Hematology Association Conference.
BL-8040’s rapid stem-cell mobilization supports stand-alone one-day treatment for stem-cell collection. Graft derived from BL-8040 treatment shows unique cell composition.

June 15th, 2015|Clinical Program BL8040, Recent News|

Initiated Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia

BioLineRx Initiated Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia.
BL-8040 remains safe and well tolerated at highest dose; continues to induce robust mobilization and leukemia cell death

May 4th, 2015|Clinical Program BL8040, Recent News|

Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment

BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment . BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months.

March 2nd, 2015|Clinical Program BL8040, Recent News|

BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform

BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform

Clinical trials in three additional indications for BL-8040 to be initiated in 2015
Development strategy presented today at BioLineRx investor meeting in New York

December 12th, 2014|Clinical Program BL8040, Recent News|

BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference

BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference

Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis

December 8th, 2014|Clinical Program BL8040, Recent News|

BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile

BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile

The amendment will include the testing of higher doses, resulting in an increase in the total study population to 70 patients. The changes were unanimously recommended by the Clinical Advisory Board.

November 3rd, 2014|Clinical Program BL8040, Recent News|

Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

The results for this additional indication for BKT-140/BL-8040 will be presented at the Society of Hematologic Oncology (SOHO) Annual Meeting. BKT-140/BL-8040 is also undergoing Phase 2 study in AML, with the final results expected in early 2015. It is also in a Phase […]

September 17th, 2014|Clinical Program BL8040, Recent News|